CD274 and neoplasm: In CheckMate040, no association was found between radiographic response and tumor cell expression of PD-L1, whereas the KEYNOTE-224 trial of pembrolizumab, which used a combined score of the tumor and microenvironment immune cell PD-L1 expression, found a correlation between PD-L1-expression and response [15, 16].